Both changes in ratio of CD8+/CD4+ T cells and FVS indicated that ccRCC-01, 03, 06 were responsive, while ccRCC-02 and 04 were resistant to toripalimab (Fig. 3C). This evidence concerns the gene CD8A and nonpapillary renal cell carcinoma.